PE firm buys majority stake in MedeAnalytics

Analytics 'growing more important with each passing day'
By Henry Powderly
09:12 AM
Share
Digital caduceus

MedeAnalytics, which develops cloud-based clinical and business intelligence tools, has sold a majority stake to private equity firm Thoma Bravo. Terms of the deal were not disclosed

San Francisco-based Thoma Bravo already holds stakes in Global Healthcare Exchange, a cloud-based provider of supply chain services for healthcare organizations, Mediware Information Systems, which provides technology for managing clinical processes like blood and medication management, and SRS software, an electronic health records platform, in addition to several other tech companies not tied to healthcare.

MedeAnalytics deals mostly with financial monitoring and risk calculation, helping the more than 1,500 providers it serves to find ways to control costs, the company said.

According to the companies, the deal will give MedeAnalytics the financial leverage to make future acquisitions.

"It was important for us to partner with an investment firm that will support our team as we build on the considerable momentum we have created in the dynamic healthcare analytics space," MedeAnalytics CEO Andy Hurd said in a statement.

While Thoma Bravo will take a majority interest in the company, prior investors Bain Capital Integral Investors and Emergence Capital Partners will continue to hold a minority stake in MedeAnalytics.

"Our partnership with MedeAnalytics is an incredible opportunity to invest in a market leader in a mission-critical sector," said Arvindh Kumar, principal at Thoma Bravo, in a statement. "Healthcare analytics is a growing market, one that plays a significant role in the healthcare industry that is only growing more important with each passing day."

This first appeared on Healthcare Finance News. It has been edited.